Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
Kai Man Xu,1 Ryan Cho,1 Toby Yiu Bong Chan2,3 1Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada; 2Division of Ophthalmology, Department of Surgery, McMaster University, Waterloo Regional Campus, Kitchener-Waterloo, Ontario, Canada; 3Ocular Health Centre, Kitchener, Ontario, Canada...
Main Authors: | Xu KM, Cho R, Chan TYB |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-07-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/retrospective-analysis-of-switching-bimatoprost-001-to-bimatoprost-003-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension
by: Saima Shahid, et al.
Published: (2024-01-01) -
Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
by: Lee D, et al.
Published: (2017-07-01) -
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Stevens A, et al.
Published: (2016-04-01) -
Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study
by: Sabrina Petricca, et al.
Published: (2022-11-01) -
Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
by: Nicholas Brennan, et al.
Published: (2017-08-01)